Antipyretics Market Overview
Antipyretics Market Size is estimated to reach $3.1 billion by 2027 and it is poised to grow at a CAGR of 1.6% over the forecast period of 2022-2027. Antipyretics agents have been used for over millennia to suppress fever from bacterial infection or viral fever. The essential elements of the fever physiologic pathway are the release of pyrogenic cytokines by inflammatory cells in response to some exogenous pyrogen (infection) and induction of cyclooxygenase (COX) 2 activation of the arachidonic acid cascade. Some of the most common forms of medicines/ products which exhibit the following characteristics are paracetamol, ibuprofen, aspirin, corticosteroids and other NSAIDs along with para-aminophenol derivative acetaminofen (Tylenol). Antipyretics are also commonly revered as antipyretic analgesic drugs. The medications work by expatiating the blood vessels present below the skin surface, thereby, providing more blood flow through the skin- providing cooling capacities to reduce fever. Owing to an increasing geriatric population exasperated by a growing number of viral and bacterial infections across the globe, the antipyretics industry is well positioned to grow during the forecast period of 2022-2027.
Antipyretics Market Report Coverage
The report: “Antipyretics Market Forecast (2022-2027)", by IndustryARC covers an in-depth analysis of the following segments in the Antipyretics Market.
- Geographically, North America held a dominant market share in the year 2021. It is owing to the strong demand curated by the U.S. leveraging stupendous medical budget sanctions and overall drug awareness and health infrastructure. However, Asia-Pacific is estimated to be the fastest-growing region owing to a rising patient pool, with a considerable rise in fever-related diseases and geriatric population.
- The growing number of viral and bacterial infections supported by the recent pandemic trends and assistance in other ailments drives the market growth. However, growing medicine prices owing to higher input costs impede the overall market growth.
- A detailed analysis of strengths, weaknesses, opportunities and threats will be provided in the Antipyretics Market Report.
Antipyretics Market Share, By Region (%), 2021.
For More Details On this report - Request For Sample
Antipyretics Market- by Product Types
Antipyretics Market based on product types can be further segmented into Paracetamol, Aspirin, NSAID and Others. Paracetamol held a dominant market share in the year 2021. Paracetamol is a commonly used medicine that helps to treat pain and reduce fever at the same time. Paracetamol is also revered as acetaminophen in the U.S. The estimated number of prescriptions for acetaminophen in 2020 within the U.S. stood at 5.6 million doses, with capsules as a preferred way of delivery according to the Clinic-Calc Database. However, NSAIDs is estimated to be the fastest-growing, with a CAGR of 2.5% over the forecast period of 2022-2027. NSAIDs are growing at a tremendous pace owing to the approvals to be sold as an OTC drug in various pharmaceutical hubs. Moreover, NSAIDs have a faster resolution time and provide multi-dimensional benefits to the person affected.
Antipyretics Market – by Sales Channel
Antipyretics Market based on sales channels can be further segmented into Hospital Pharmacies, Drug stores & Retail Pharmacies, Online Pharmacies and Others. Drug Stores and Retail Pharmacies held a dominant market share in the year 2021. It is owing to the vast majority of the following channels in major economies. As per Statista, nearly 800,000 pharmacies are spread across the Indian region and exhibit a dominant medical distribution channel. Moreover, various online retailers are establishing an offline presence in metro cities to deliver higher customer satisfaction and compete in a highly competitive market space. However, Online Pharmacies are estimated to be the fastest-growing with a CAGR of 3.0% over the forecast period of 2022-2027. It is owing to the growing internet penetration in a majority of the population, with brands launching omnichannel strategies with attractive subscription-based discounts.
Antipyretics Market – by Geography
Antipyretics Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America dominated the market with a share of 31% in 2021. The region suffered a heightened number of COVID-19 cases and deaths, thereby, with a plethora of patients reporting fever as a common symptom- the sales of antipyretics rocketed in the year. From the onset of the pandemic, cases per one-million population stood at 288,647 in the U.S. as per the New York Times. However, Asia-Pacific is estimated to be the fastest-growing, with a CAGR over the forecast period of 2022-2027. It is owing to the growing geriatric population with other forms of chronic and viral illnesses spread through varietals of reasons and sources. The following will result in the growth of the market during the forecast period.
Antipyretics Market Drivers
Long-Covid Cases Along with Heightened Medical Awareness of the Product Class have Provided Growth Prerogatives to the Market.
As per Frontier.Org, fever tends to remain one of the typical symptoms of COVID-19. Based on a meta-analysis by researchers, fever as a symptom was present in nearly 85.6% of all COVID-19 cases during the course of the disease. Furthermore, medicines proliferated under the category of analgesics and antipyretics held a larger growth which pushed the market further. As per Nature 2021, nearly 26 randomized trials are underway for treating long-COVID. Of the candidates present, nearly 9 of the drugs are anti-inflammatory or antipyretics, which work on reducing aches and fever. Lastly, the awareness pertinent to the availability and usage of antipyretics has grown high which will continue to aid the market.
The Growing Number of Bacterial and Viral Infections Across the Globe has Curated Tremendous Demand for the Antipyretics Market.
The bacterial and viral infection rates have been climbing high owing to various societal practices and the evolution of bacterial and viral classes to infect humankind to a further extent. Owing to the leniency post-COVID, the number of flu and viral cases is driving the demand for antipyretics. According to CDC, within the last flu season of 2022- around 4.7 million illnesses and 47,000 hospitalizations have taken place. The following represents an uptick from the number which was only 2038 in September 2020. Lastly, bacterial evolution continues to increase the cases of a plethora of diseases, with fever as a primary symptom. Owing to the following, the market will register growth.
Antipyretics Market Challenges
The Growing Prices for Basic Antipyretics Drugs have been Registering a Strong QOQ Price Growth Impeding the Market Growth.
Owing to the pandemic, API prices have been soaring resulting in an increased product price. For example, paracetamol prices have risen to the $11.29 to $13.44 per kg range, up from around $4.0 per kg before the COVID-19 pandemic. Moreover, value chain resilience towards certain countries has impeded market growth. For example, China produces a sizable API content- owing to developing COVID-19 situations with port closures and other trade restrictions posed by the challenges of the Russia-Ukraine War continue to impede the market.
Antipyretics Industry Outlook
Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Antipyretics Market. The top 10 companies in the Antipyretics Market are:
- Dr. Reddy's Laboratories
- CIPLA Ltd
- Sun Pharmaceuticals
- Glenmark Pharmaceuticals
- Pfizer Inc.
- GSK Pharmaceuticals
- BASF SE
- Novartis AG
- LUPIN Limited
- ZYDUS Life
- In May 2022, Strides Pharma received approval from the U.S. FDA for Ibuprofen OTC oral suspension. The following move strengthens the company’s position in the country for analgesics and antipyretics. The product will be manufactured at the company’s facility in Bengaluru.
- In February 2022, the sale of combination products in Germany containing both paracetamol and ibuprofen without a prescription will allow marketers to increase their revenue attributes from the country. The drug prescription ordinance was signed and approved by the Federal Council of Germany.
- In January 2020, Cumberland Pharmaceuticals- a Nashville Pharma Company launched a newer form of injectable ibuprofen that researchers claim can drastically reduce the use of opioid painkillers in hospitals and stop addictions before they begin. The product is backed by extensive on-site review within which it was found that post-surgery in a hospital in Phoenix, opioid usage shrunk by 58%.
Report Code- HCR 0116
Report Code- HCR 0952
Report Code- CMR 48846
For more Chemicals and Materials Market reports, please click here